Literature DB >> 36161411

Double Immunohistochemical Staining on Formalin-Fixed Paraffin-Embedded Tissue Samples to Study Vascular Co-option.

Tiziana Annese1,2, Mariella Errede3, Michelina De Giorgis3, Loredana Lorusso3, Roberto Tamma3, Domenico Ribatti3.   

Abstract

Vascular co-option is a non-angiogenic mechanism whereby tumor growth and progression move on by hijacking the pre-existing and nonmalignant blood vessels and is employed by various tumors to grow and metastasize.The histopathological identification of co-opted blood vessels is complex, and no specific markers were defined, but it is critical to develop new and possibly more effective therapeutic strategies. Here, in glioblastoma, we show that the co-opted blood vessels can be identified, by double immunohistochemical staining, as weak CD31+ vessels with reduced P-gp expression and proliferation and surrounded by highly proliferating and P-gp- or S100A10-expressing tumor cells. Results can be quantified by the Aperio Colocalization algorithm, which is a valid and robust method to handle and investigate large data sets.
© 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Angiogenesis; Blood vessel; Glioblastoma; Image analysis; Immunohistochemistry; Quantification; Vascular co-option

Mesh:

Substances:

Year:  2023        PMID: 36161411     DOI: 10.1007/978-1-0716-2703-7_8

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  69 in total

Review 1.  Chemotherapy in glioma.

Authors:  Walter Taal; Jacoline E C Bromberg; Martin J van den Bent
Journal:  CNS Oncol       Date:  2015-04-23

2.  CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014.

Authors:  Quinn T Ostrom; Haley Gittleman; Peter Liao; Toni Vecchione-Koval; Yingli Wolinsky; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2017-11-06       Impact factor: 12.300

Review 3.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

4.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

5.  Quantitative expression of serum biomarkers involved in angiogenesis and inflammation, in patients with glioblastoma multiforme: correlations with clinical data.

Authors:  Roxana Chiorean; Ioana Berindan-Neagoe; Cornelia Braicu; Ioan Stefan Florian; Daniel Leucuta; Doinita Crisan; Valentin Cernea
Journal:  Cancer Biomark       Date:  2014       Impact factor: 4.388

Review 6.  Prospects of biological and synthetic pharmacotherapies for glioblastoma.

Authors:  David B Altshuler; Padma Kadiyala; Felipe J Nuñez; Fernando M Nuñez; Stephen Carney; Mahmoud S Alghamri; Maria B Garcia-Fabiani; Antonela S Asad; Alejandro J Nicola Candia; Marianela Candolfi; Joerg Lahann; James J Moon; Anna Schwendeman; Pedro R Lowenstein; Maria G Castro
Journal:  Expert Opin Biol Ther       Date:  2020-01-20       Impact factor: 4.388

7.  Longer-term (≥ 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis.

Authors:  Michael T C Poon; Cathie L M Sudlow; Jonine D Figueroa; Paul M Brennan
Journal:  Sci Rep       Date:  2020-07-15       Impact factor: 4.379

8.  Clinical features associated with the efficacy of chemotherapy in patients with glioblastoma (GBM): a surveillance, epidemiology, and end results (SEER) analysis.

Authors:  Jieqiong Wen; Wanbin Chen; Yayun Zhu; Pengbo Zhang
Journal:  BMC Cancer       Date:  2021-01-19       Impact factor: 4.430

9.  Reclassification of Glioblastoma Multiforme According to the 2021 World Health Organization Classification of Central Nervous System Tumors: A Single Institution Report and Practical Significance.

Authors:  George S Stoyanov; Emran Lyutfi; Reneta Georgieva; Radoslav Georgiev; Deyan L Dzhenkov; Lilyana Petkova; Borislav D Ivanov; Ara Kaprelyan; Peter Ghenev
Journal:  Cureus       Date:  2022-02-01

10.  Optimal Timing of Radiotherapy Following Gross Total or Subtotal Resection of Glioblastoma: A Real-World Assessment using the National Cancer Database.

Authors:  Samantha M Buszek; Karine A Al Feghali; Hesham Elhalawani; Neil Chevli; Pamela K Allen; Caroline Chung
Journal:  Sci Rep       Date:  2020-03-18       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.